Moreover, inhibition of CXCR4/SDF1 axis using AMD3100 (Plerixafor), an agonist for CXCR4, has been shown to decrease AML tumor burden in AML leukaemic mice in combination with conventional AML chemotherapy [26]. Here, CXCL12 is linked to acute myeloid leukemia.